Sutro Biopharma (STRO) and Compugen (CGEN) Head-To-Head Comparison

Share on StockTwits

Sutro Biopharma (NASDAQ:STRO) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, profitability, analyst recommendations, risk and valuation.

Insider & Institutional Ownership

47.4% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 25.4% of Compugen shares are owned by institutional investors. 28.9% of Sutro Biopharma shares are owned by company insiders. Comparatively, 9.5% of Compugen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Sutro Biopharma and Compugen, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sutro Biopharma 0 0 5 0 3.00
Compugen 0 0 1 0 3.00

Sutro Biopharma presently has a consensus price target of $22.75, indicating a potential upside of 121.73%. Compugen has a consensus price target of $9.00, indicating a potential upside of 162.39%. Given Compugen’s higher possible upside, analysts plainly believe Compugen is more favorable than Sutro Biopharma.

Earnings & Valuation

This table compares Sutro Biopharma and Compugen’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sutro Biopharma $38.42 million 6.12 -$35.32 million ($6.13) -1.67
Compugen $17.80 million 9.88 -$22.60 million ($0.41) -8.37

Compugen has lower revenue, but higher earnings than Sutro Biopharma. Compugen is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sutro Biopharma and Compugen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sutro Biopharma N/A N/A N/A
Compugen N/A -61.77% -46.53%

Summary

Sutro Biopharma beats Compugen on 7 of the 11 factors compared between the two stocks.

About Sutro Biopharma

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

About Compugen

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations. Its product pipeline consists of COM701, a monoclonal antibody designed to block the interaction of PVRIG with its cognate ligand, PVRL2; CGEN-15001T, an immuno-oncology therapeutic program for ILDR2; and COM902, a therapeutic antibody candidate for its TIGIT program. The company's pipeline also comprises therapeutic proteins include CGEN-15001, a fusion protein drug candidate for autoimmune diseases, including extracellular domain of ILDR2 and an IgG Fc domain. Compugen Ltd. has a clinical trial collaboration with Bristol-Myers Squibb Company to evaluate the safety of COM701 in combination with Bristol-Myers Squibb's programmed death-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. The company was incorporated in 1993 and is headquartered in Holon, Israel.

Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Barry Zwarenstein Sells 7,663 Shares of Five9 Inc  Stock
Barry Zwarenstein Sells 7,663 Shares of Five9 Inc Stock
Venture Fund Vii L.P. Arch Sells 63,000 Shares of Syros Pharmaceuticals Inc  Stock
Venture Fund Vii L.P. Arch Sells 63,000 Shares of Syros Pharmaceuticals Inc Stock
Insider Selling: Neogen Co.  Director Sells 5,000 Shares of Stock
Insider Selling: Neogen Co. Director Sells 5,000 Shares of Stock
Neogen Co.  Director Sells $314,650.00 in Stock
Neogen Co. Director Sells $314,650.00 in Stock
Insider Selling: Airgain Inc  CEO Sells 22,464 Shares of Stock
Insider Selling: Airgain Inc CEO Sells 22,464 Shares of Stock
Insider Selling: Bottomline Technologies  Insider Sells 9,925 Shares of Stock
Insider Selling: Bottomline Technologies Insider Sells 9,925 Shares of Stock


© 2006-2019 Ticker Report